Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates

Area of Science:

• Radiochemistry
• Nuclear Medicine
• Immunotherapy

Background:

• Radioimmunotherapy (RIT) using 90Y-labeled immunoconjugates shows clinical promise.
• 1,4,7,10-tetraazacyclododecane-N,N',N",N"-tetraacetic acid (DOTA) provides stable 90Y chelation, minimizing bone toxicity.
• Current 90Y-DOTA immunoconjugate yields are often below 50%, hindering RIT practicality.

Purpose of the Study:

• To optimize radiolabeling conditions for 90Y-DOTA immunoconjugates.
• To improve product yields for practical RIT applications.
• To establish dependable and cost-effective preparation methods for 90Y-DOTA pharmaceuticals.

Main Methods:

• Conjugation of (S) 2-[p-(bromoacetamido)benzyl]-DOTA (BAD) to Lym-1 antibody via 2-iminothiolane (2IT).
• Kinetic studies of 90Y labeling in various buffers, pH, concentrations, and temperatures.
• Evaluation of optimal conditions using 2IT-BAD-Lym-1 and DOTA-peptide-chimeric L6 immunoconjugates.

Main Results:

• Ammonium acetate buffer (0.5 M) at pH 7-7.5 and 37°C yielded the highest 90Y uptake.
• Optimal conditions (30-min reaction time) resulted in a mean product yield of 91% ± 8%.
• Achieved specific activity of 74-130 MBq/mg and 100% ± 11% immunoreactivity.

Conclusions:

• Optimized 90Y-DOTA chelation conditions enhance RIT feasibility.
• This optimization facilitates dependable and cost-effective preparation of 90Y-DOTA pharmaceuticals.
• Improved yields are crucial for the clinical success of 90Y RIT.